Navigation Links
Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference
Date:9/3/2014

SYDNEY, Sept. 3, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will present at the Rodman & Renshaw 16th Annual Healthcare Conference on Wednesday, September 10th in New York.  Dr. Kelly will provide an overview of the two Novogen first-in-class drug technology platforms in the field of oncology.  His presentation will take place at the New York Palace Hotel and will begin at 10:25am.

About Novogen LimitedNovogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc, with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on the Company's website, www.novogen.com.

For more information please contact:Corporate ContactMedia enquiriesExecutive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com 
+61 (0) 2 9472 4100In the USA:Lazar Partners
Novogen@lazarpartners.com 
+1 212-867-1762Investors enquiriesIn Australia:In the USA:Lazar Partners

Novogen@lazarpartners.com

+1 212-867-1762

Dr. Douglas Pretsell

Instinctif Partners

+61 (0) 3 9657 0706In ROW:Sue Charles

Instinctif Partners

+44 (0) 20 7457 2020Logo - http://photos.prnewswire.com/prnh/20131220/NY36990LOGO 


'/>"/>
SOURCE Novogen Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Novogen Announces Results of General Meeting of Shareholders
2. Novogen Receives Funding Support To Commence Studies In Muscular Dystrophy
3. Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC, Pfizer and Infinity Pharmaceuticals
4. Novogen Announces Merger Agreement With Kai Medical And Distribution Of Mei Pharma Shares
5. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
6. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
7. Ascendant Solutions, Inc. Announces Completion of Second Pharmacy Acquisition by Its Doughertys Holdings Subsidiary
8. Integrity Applications, Inc. Announces Equity Financing of $3.0 Million
9. GenSpera Announces Generic Name "Mipsagargin" for Lead Drug Candidate G-202 per Recommendation by World Health Organization
10. Cepheid Announces European Release of Xpert TV, a Next-Generation Molecular Test for Rapid and Accurate Identification of Trichomonas vaginalis Infections
11. MarketResearch.com Announces Addition of New Kalorama Information Content to Diagnostics Knowledge Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators are used to treat ... if one isn’t accessible in certain locations, the risk of death can be ... with this idea," said an inventor from Ridgecrest, Calif. , The MOBILE AUTOMATED ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... SABRE Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from ... in Educational Leadership and Administration at St. Thomas University in Miami, Florida, was ...
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice ... celebrating the one year anniversary of its Houston-Fallbrook facility. , “We are ... Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... and more products at customers’ doorstep. According to Smart Mart, customers can now ... stated to offer wearable, and customers can find clothing at discounted prices. Apart ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for Medical ... p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device manufacturing ... The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a warning ...
Breaking Medicine News(10 mins):